Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2021 – Stockhouse

HONG KONG, Aug. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2021 ended June 30, 2020.

First Quarter of Fiscal 2021 Highlights

"Despite the ongoing challenges brought on by the 2019 novel coronavirus (COVID-19) pandemic and sluggish consumer sentiment, we recorded 17,233 new subscribers during the first quarter of fiscal 2021," commented Ms. Ting Zheng, Chairperson and Chief Executive Officer of GCBC. "As we continue to navigate the current situation, we will remain vigilant to the long-term consequences of the pandemic and the constraints it has cast upon our business environment, as well as any potential developments in the regulatory regime that governs China's cord blood banking industry. We will also continue to pursue business opportunities as we expand our service offerings to support the long-term growth of the Company."

Summary - First Quarter Ended June 30, 2019 and 2020

Three Months Ended June 30,

2019

2020

(in thousands)

RMB

RMB

US$

Revenues

273,375

280,913

39,761

Gross Profit

227,626

237,450

33,609

Operating Income[3]

112,386

133,509

18,897

Change in Fair Value of Equity Securities

9,979

18,405

2,605

Net Income Attributable to the Company's Shareholders

108,344

132,509

18,756

Earnings per Ordinary Share(RMB/US$)

Basic

0.89

1.09

0.15

Diluted

0.89

1.09

0.15

Revenue Breakdown (%)

Processing Fees and Other Services

61.3%

57.5%

Storage Fees

38.7%

42.5%

New Subscribers (persons)

20,815

17,233

Total Accumulated Subscribers (persons)

770,699

849,933[1]

Summary - Selected Cash Flow Statement Items

Three Months Ended June 30,

2019

2020

(in thousands)

RMB

RMB

US$

Net cash provided by operating activities

169,756

99,829

14,131

Net cash used in investing activities

(6,625)

(7,444)

(1,054)

Net cash provided by financing activities

-

-

-

First Quarter of Fiscal 2021 Financial Results

REVENUES. Revenues increased by 2.8% YoY to RMB280.9 million ($39.8 million) in the first quarter of fiscal 2021. The increase was mainly driven by the larger client base and the increase in storage fee revenues, which outweighed the decrease in processing fee revenues.

By the end of June 2020, the Company's accumulated subscriber base grew to 849,933[1] and revenues generated from storage fees increased by 12.7% YoY to RMB119.3 million ($16.9 million) in the reporting quarter. Storage fee revenues increased to 42.5% of total revenues from 38.7% in same period last year.

During the quarter, the COVID-19 pandemic continued to affect the Company's hospital channels and business operations, as well as general consumer sentiment-resulting in the new subscriber numbers for the reporting period decreasing by 17.2% YoY and 6.8% quarter-over-quarter to 17,233. Revenues generated from processing fees and other services in the reporting quarter decreased by 3.5% YoY to RMB161.6 million ($22.9 million), with decreases in such activities offset in part by the full period contribution of the revised processing fee pricing.

GROSS PROFIT. Gross profit for the reporting quarter increased by 4.3% YoY to RMB237.5 million ($33.6 million). Gross margin improved to 84.5% from 83.3% in the prior year period.

OPERATING INCOME. Facing challenges caused by the pandemic, the Company took measures to control operating expenses. As a result, operating income for the reporting quarter increased by 18.8% YoY to RMB133.5 million ($18.9 million). Operating margin expanded to 47.5% in the reporting quarter from 41.1% in the prior year period. Depreciation and amortization expenses for the first quarter were RMB12.4 million ($1.7 million), similar to that in the prior year period. Non-GAAP operating income[2] improved by 16.8% YoY to RMB145.9 million ($20.6 million).

Research and Development Expenses. Research and development expenses for the first quarter decreased by 7.6% YoY to RMB4.3 million ($0.6 million).

Sales and Marketing Expenses. As the Company continued to tighten sales and marketing expenses and maintain only essential promotional activities, sales and marketing expenses for the reporting quarter decreased by 9.2% YoY to RMB55.1 million ($7.8 million). Sales and marketing expenses as a percentage of revenues were down to 19.6% from 22.2% in the prior year period.

General and Administrative Expenses. General and administrative expenses for the first quarter decreased by 10.8% YoY to RMB44.5 million ($6.3 million), mainly driven by lower staff costs, fees, overhead and provisions. General and administrative expenses as a percentage of revenues decreased to 15.9% from 18.3% in the prior year period.

OTHER INCOME AND EXPENSES.

Change in Fair Value of Equity Securities. In the first quarter, the Company recognized an increase in fair value of equity securities, or "mark-to-market gains," of RMB18.4 million ($2.6 million), up from RMB10.0 million in the prior year period. The changes were mainly attributable to the valuation of the Company's investments in equity securities.

NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. Due to the increase in operating income and the increase in fair value of equity securities, income before income tax for the first quarter increased by 24.0% YoY to RMB160.4 million ($22.7 million). Income tax expense for the reporting quarter was RMB26.0 million ($3.7 million). Net income attributable to the Company's shareholders for the reporting quarter increased by 22.3% YoY to RMB132.5 million ($18.8 million). Net margin for the first quarter improved by 7.6 percentage points to 47.2%.

EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the first quarter fiscal 2021 increased by 22.5% YoY to RMB1.09($0.15).

Corporate Developments

On November 11, 2019, the Company appointed Mr. Jack Chow as an independent non-executive director ("INED") of the Board. Mr. Chow has extensive professional experience and a broad network in the finance and investment industry. He replaced Mr. Mark Chen as a member of the Audit Committee and Ms. Jennifer Weng as a member of the Special Committee. Mr. Chow also joined the Board's Compensation Committee and Nominating and Corporate Governance Committee.

On February 6, 2020, the Company appointed Mr. Jacky Cheng as an INED of the Board. Mr. Cheng has extensive professional experience and knowledge in legal and compliance and Chinese laws. He joined the Board's Compensation Committee as a member and the Company's Special Committee as a member. Currently, the Special Committee is composed of four members, including Mr. Mark Chen, Dr. Ken Lu, Mr. Jack Chow, and Mr. Jacky Cheng.

Conference Call

The Company will host a conference call at 8:00 a.m. ET on Tuesday, August 25, 2020 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http://ir.globalcordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for seven days at the same URL above. Listeners can also access the call by dialing 1-855-824-5644 or 1-646-722-4977 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 11021450#.

[1] During the three months ended June 30, 2020, 17,233 new subscribers were recruited. The Company reclassified 394 private cord blood units as donated cord blood units during the three months ended June 30, 2020, after the Company determined that the recoverability of these prior private cord blood banking subscribers was remote. Therefore, the Company terminated their subscription services according to the subscription contracts and these units are being treated as if they were donated cord blood units and will be part of the Company's non-current inventories. Hence, the net accumulated subscriber base was 849,933 as of June 30, 2020.

[2] See exhibit 3 to this press release for a reconciliation of non-GAAP operating income to exclude the non-cash items related to the depreciation and amortization expenses to the comparable financial measure prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").

[3] The reported operating income for the three months ended June 30, 2019 and 2020 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB12.4 million and RMB12.4 million ($1.7 million), respectively.

Use of Non-GAAP Financial Measures

GAAP results for the three months ended June 30, 2020 include non-cash items related to depreciation and amortization expenses. To supplement the Company's unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company's management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company's historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.

About Global Cord Blood Corporation

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at: http://www.globalcordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

The rest is here:

Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2021 - Stockhouse